jcp conference-coverage

Conference Coverage

Conference Coverage

Benefits of BCL-2 Targeting Treatment for Patients With Chronic Lymphocytic Leukemia

01/29/2024

Featuring Asher Chanan-Khan, MD

Featuring Asher Chanan-Khan, MD ...

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Asher Chanan-Khan, MD, argued in favor of treatments targeting BCL-2 for patients with chronic lymphocytic leukemia (CLL).

At the 2023 Lymphoma, Leukemia &...

01/29/2024

Lymphoma, Leukemia & Myeloma Network

News

Efficacy and Safety of Real-World Treatments of Teclistamab for Patients with Pretreated Relapsed/Refractory Multiple Myeloma

01/29/2024

Grace Taylor

Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed refractory multiple myeloma who have had at least four prior lines of therapy.

Danai Dima, MD, and colleagues...

01/29/2024

Journal of Clinical Pathways

Conference Coverage

Belzutifan Improves Quality of Life Among Patients With Advanced Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Thomas Powles, MBBS, MD

Featuring Thomas Powles, MBBS, MD ...

Thomas Powles, MBBS, MD, discusses results from the phase 3 LITESPARK-005 study which compared patient-reported outcomes among patients treated with belzutifan and everolimus for advanced/metastatic clear cell renal cell carcinoma.

Thomas Powles, MBBS, MD,...

01/27/2024

Oncology

Videos

KEYNOTE-564 Study of Adjuvant Pembrolizumab vs Placebo for the Treatment of Clear Cell Renal Cell Carcinoma

01/27/2024

Featuring Toni Choueiri, MD

Toni Choueiri, MD, gives a summary of the findings from the phase 3 KEYNOTE-564 study, which analyzed the overall survival of pembrolizumab for the treatment of clear renal cell carcinoma.

Toni Choueiri, MD, gives a...

01/27/2024

Journal of Clinical Pathways

Conference Coverage

Enfortumab Vedotin Plus Pembrolizumab Potential New Standard of Care for Advanced Urothelial Carcinoma in the First-Line Setting

01/26/2024

Featuring Michiel van der Heijden, MD

Featuring Michiel van der Heijden, MD...

Michiel van der Heijden, MD, discusses the subgroup analyses of the phase 3 EV-302 study, evaluating enfortumab vedotin plus pembrolizumab among patients with locally advanced or metastatic urothelial carcinoma in the first-line setting.

Michiel van der Heijden, MD,...

01/26/2024

Oncology

Conference Coverage

Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer

01/25/2024

Stephanie Holland

Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...

Results from the ongoing phase 3...

01/25/2024

Oncology

Videos

How Patient-Centered Cancer Symptom Management Can Help Improve Patient Outcomes

01/25/2024

Featuring David F. Lobach, MD, PhD

Featuring David F. Lobach, MD, PhD ...

David F. Lobach, MD, PhD, vice president of Health Informatics Research for Elimu Informatics, provides an overview of the Cancer Symptom Management system as a clinical decision support tool for a patient-centered treatment approach.

David F. Lobach, MD, PhD, vice...

01/25/2024

Journal of Clinical Pathways

Videos

Clinical Decision Support in Cancer Care: Why the Patient’s Voice Matters

01/24/2024

Featuring Mary E. Cooley, PhD, RN, FAAN

Featuring Mary E. Cooley, PhD, RN, FA...

Mary E. Cooley, PhD, RN, FAAN, Dana-Farber Cancer Institute, discusses the advantages of clinical decision support in managing patient care and how it differs from the typical standard of care.

Mary E. Cooley, PhD, RN, FAAN,...

01/24/2024

Journal of Clinical Pathways

Videos

Expanding Access to Care Through Academic-Community Cancer Care Collaboration

01/23/2024

Featuring Harlan Levine, MD

Harlan Levine, MD, highlights the benefits of the collaboration between community cancer centers and academic medical centers, including allowing for more access to patient care.

Harlan Levine, MD, highlights...

01/23/2024

Journal of Clinical Pathways

Jeanne Tie, MBChB, MD, Peter MacCallum Cancer Centre

Videos

Circulating Tumor DNA-Guided vs Standard Management of Locally Advanced Rectal Cancer

01/20/2024

Featuring Jeanne Tie, MBChB, MD

Featuring Jeanne Tie, MBChB, MD ...

Professor Jeanne Tie, MBChB, FRACP, MD, discusses results from the AGITG DYNAMIC-Rectal study, which explored a ctDNA-guided approach to adjuvant chemotherapy following neoadjuvant chemoradiation for locally advanced rectal cancer.

Professor Jeanne Tie, MBChB,...

01/20/2024

Oncology

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products